Faruqi & Faruqi Investigates agilon health for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy AGL?
Source: Globenewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating agilon health for potential securities law violations between February 26 and August 4, 2025, urging affected investors to reach out to discuss their legal rights.
- Misguided Financial Guidance: The lawsuit alleges that agilon health and its executives issued misleading financial guidance for 2025 without disclosing known industry headwinds, resulting in significant investor losses.
- Stock Price Plunge: Following agilon health's August 4, 2025 press release announcing the suspension of its 2025 financial guidance, the stock plummeted by 51.5% the next day, reflecting market disappointment in the company's outlook.
- Class Action Opportunity: Investors have until March 2, 2026, to apply as lead plaintiffs in the class action lawsuit, with Faruqi & Faruqi encouraging anyone with relevant information to contact them for assistance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGL is 0.98 USD with a low forecast of 0.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
1 Buy
7 Hold
2 Sell
Hold
Current: 0.828
Low
0.50
Averages
0.98
High
1.50
Current: 0.828
Low
0.50
Averages
0.98
High
1.50
About AGL
agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating agilon health for potential securities law violations between February 26 and August 4, 2025, urging affected investors to reach out to discuss their legal rights.
- Misguided Financial Guidance: The lawsuit alleges that agilon health and its executives issued misleading financial guidance for 2025 without disclosing known industry headwinds, resulting in significant investor losses.
- Stock Price Plunge: Following agilon health's August 4, 2025 press release announcing the suspension of its 2025 financial guidance, the stock plummeted by 51.5% the next day, reflecting market disappointment in the company's outlook.
- Class Action Opportunity: Investors have until March 2, 2026, to apply as lead plaintiffs in the class action lawsuit, with Faruqi & Faruqi encouraging anyone with relevant information to contact them for assistance.
See More
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health and certain officers, seeking damages for investors who purchased Agilon securities between February 26 and August 4, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- False Statement Allegations: The complaint alleges that throughout the class period, defendants made false and misleading statements, particularly regarding 2026 financial guidance, indicating a lack of awareness of material industry headwinds, which could lead to substantial investor losses.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by March 2, 2026, to share in any potential recovery from the lawsuit, reflecting the legal team's commitment to protecting investor rights and interests.
- Fee Structure: The law firm operates on a contingency fee basis, meaning they will only charge fees if they successfully recover funds, thereby reducing the financial burden on investors and increasing their willingness to participate in the lawsuit.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, allowing them to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Agilon Health made false and misleading statements during the class period, resulting in investor losses when the true information was revealed, indicating significant missteps in the company's financial guidance and strategic actions.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in handling such cases, prompting investors to choose experienced legal counsel wisely.
See More
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Agilon Health, Inc. for investors who purchased securities between February 26, 2025, and August 4, 2025, highlighting significant misstatements in the company's financial guidance.
- False Statement Allegations: The lawsuit alleges that Agilon issued unrealistic financial guidance during the class period and failed to disclose major industry challenges, resulting in investor losses once the true information was revealed.
- Investor Rights Protection: Investors must apply by March 2, 2026, to be appointed as lead plaintiffs in the lawsuit, indicating the potential impact and importance of this case for affected investors.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in shareholder rights, offering no-cost legal consultations to help investors understand their rights and options regarding the lawsuit.
See More
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that March 2, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Agilon Health securities between February 26 and August 4, 2025.
- Leadership Change Impact: On August 4, 2025, Agilon announced the departure of its President and CEO, which led to the company missing its second-quarter earnings estimates and suspending its 2025 guidance, indicating increased market uncertainty.
- Stock Price Plunge: Following the leadership change and disappointing earnings report, Agilon's stock price plummeted by 51.5% to close at $0.88 per share on August 5, 2025, significantly harming investor interests.
- False Statements Allegations: The lawsuit alleges that Agilon made materially misleading statements during the class period, failing to disclose industry headwinds that affected its business outlook, leading investors to misjudge the company's prospects.
See More
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against Agilon Health Inc. (NYSE:AGL) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and August 4, 2025.
- False Statements Allegation: The complaint alleges that Agilon made false and misleading statements, overstating the effectiveness of its strategic actions, which resulted in significant investor losses when the truth emerged, highlighting serious issues with the company's financial transparency.
- Investor Rights Protection: Affected shareholders are encouraged to contact the Schall Law Firm before March 2, 2026, to participate in the lawsuit and seek compensation, indicating potential legal risks for the company regarding its accountability.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not currently represented by an attorney, underscoring the importance of taking timely action to protect their rights.
See More











